Pharma & Life Sciences

FAK Inhibitor Patent for NRAS Mutant Tumor Treatment

EPO published patent application EP4062914A1 by Inxmed (Nanjing) Co., Ltd. covering FAK (Focal Adhesion Kinase) inhibitor compositions for treating tumors harboring NRAS mutations. The patent application designates 38 European contracting states including major markets such as Germany, France, and the UK. IPC classifications indicate applications in pharmaceutical compositions (A61K) and cancer therapeutics (A61P 35/00).

NK Cell Fusion Protein Anticancer Treatment Composition

The European Patent Office published EP4067481A1, a patent application for a composition comprising NK cells and a fusion protein combining IL-2 protein and CD80 protein for anticancer treatment. Applicants GI Cell, Inc. and GI Innovation, Inc. seek exclusive IP rights covering the composition, methods of preparation, and therapeutic use across 38 designated European states.

Fulvestrant Pharmaceutical Composition

EPO published patent application EP4074304A1 by Shanghai Bocimed Pharmaceutical Co., Ltd. for a fulvestrant pharmaceutical composition with preparation method. The application covers the antineoplastic drug formulation (A61P 35/00) and is published with examination complete, granting enforceable patent rights across 38 designated EU member states and extension states.

CMS Launches First Wave HealthTech Ecosystem Tools, 700+ Orgs Pledged

CMS announced the First Wave Launch of its HealthTech Ecosystem, featuring interoperable digital tools for patient data access and streamlined care. Over 700 organizations have pledged support for the initiative, which aims to modernize healthcare delivery by replacing traditional paperwork with digital-first solutions.

Health Canada Consults on Antimicrobial Drug CAN-AWaRe Classification

Health Canada has opened a 60-day public consultation on the proposed Canadian Access, Watch, Reserve (CAN-AWaRe) classification framework for antimicrobial drugs for human use. The consultation runs until June 8, 2026, and seeks feedback from healthcare professionals, industry, academia, and public health agencies on the proposed classification of antibacterial drugs. Comments will inform the finalization of the CAN-AWaRe framework.

OSHA Logging Operations Standard

OSHA has issued a final rule updating the Logging Operations Standard (29 CFR 1910.266), addressing safety requirements for chainsaws, machine guarding, personal protective equipment, and training in logging workplaces. The revised standard affects approximately 1,600 logging establishments with 54,000 workers.

Elekta Cervical/Intrauterine Brachytherapy System Safety Recall

ANSM published safety alert R2610148 informing healthcare facilities of a medical device safety action by Elekta regarding its cervical/intrauterine brachytherapy system. Users of affected devices have received direct notification from Elekta. The recall is effective April 9, 2026, and healthcare providers using this radiation therapy equipment must take immediate action.

Advanced Bionics Cochlear Implant Battery Compartment Recall, 847 Units

ANSM recorded a lot withdrawal by Advanced Bionics LLC for cochlear implant battery compartments (model ZN Air M CI-5501). The action, registered as R2609192, affects 847 units. Health establishments received direct notification from the company with instructions for identifying and returning affected devices.

Recall Mycology Yeastone Broth 11ML Remel - R2609813

ANSM registered safety action R2609813 for Mycology Yeastone Broth 11ML Remel following a lot withdrawal initiated by Thermo Fisher. Medical biology laboratories that received the affected product have been notified directly by Thermo Fisher. This recall addresses a safety concern with specific lots of the reagent used in mycological testing.

DEX Ophthalmic Forceps Recall Katalyst Surgical Carl Zeiss Meditec

ANSM issued safety alert R2609552 informing French health establishments of a recall by Carl Zeiss Meditec for DEX ophthalmic forceps and scissors manufactured by Katalyst Surgical LLC. Affected health facilities must remove the devices from use and contact the manufacturer directly. The safety action letter was published April 9, 2026.